Fosfomycin for treatment of multidrug-resistant pathogens causing urinary tract infection: A real-world perspective and review of the literature
Among 47 patients with urinary tract infections (UTIs) due to multidrug-resistant (MDR) bacteria, treatment with fosfomycin resulted in clinical cure rates of 87% and 94% at 48 hours and 14 days, respectively. Response rates did not vary across pathogens. Our retrospective, observational findings su...
Gespeichert in:
| Veröffentlicht in: | Diagnostic microbiology and infectious disease 2019-11, Vol.95 (3), p.114856-114856, Article 114856 |
|---|---|
| Hauptverfasser: | , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 114856 |
|---|---|
| container_issue | 3 |
| container_start_page | 114856 |
| container_title | Diagnostic microbiology and infectious disease |
| container_volume | 95 |
| creator | Babiker, Ahmed Clarke, Lloyd Doi, Yohei Shields, Ryan K |
| description | Among 47 patients with urinary tract infections (UTIs) due to multidrug-resistant (MDR) bacteria, treatment with fosfomycin resulted in clinical cure rates of 87% and 94% at 48 hours and 14 days, respectively. Response rates did not vary across pathogens. Our retrospective, observational findings support fosfomycin treatment against MDR pathogens causing UTIs. |
| doi_str_mv | 10.1016/j.diagmicrobio.2019.06.008 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2258746938</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0732889319302238</els_id><sourcerecordid>2258746938</sourcerecordid><originalsourceid>FETCH-LOGICAL-c446t-90f0ca2a45e6928029dc9fbd6c933753bd3d3b67a93d03c6e0d25b5c02d8c2373</originalsourceid><addsrcrecordid>eNqNkUFv1DAQhS0EokvhLyCLE5eEiZ04cW9VoVCpEhc4W4492XqV2MF2WvVf9Cfj1RbEkZMlz3vzNO8j5EMDdQON-HSordP7xZkYRhdqBo2sQdQAwwuya4ZeVgA9vCQ76DmrhkHyM_ImpQNAw2QLr8kZbzj0g-h35Ok6pCksj8Z5OoVIc0SdF_SZhoku25ydjdu-iphcyrp8rzrfhT36RI3ekvN7ukXndXwsVm0ydX5Ck13wF_SSlmVz9RDibOmKMa3HyT1S7W0Z3Tt8OKbkO6Szyxh13iK-Ja8mPSd89_yek5_XX35cfatuv3-9ubq8rUzbilxJmMBoptsOhWQDMGmNnEYrjOS87_houeWj6LXkFrgRCJZ1Y2eA2cEw3vNz8vG0d43h14Ypq8Ulg_OsPYYtKca6oW-F5EORXpykpfCUIk5qjW4pJ6sG1JGIOqh_iagjEQVCFSLF_P45ZxsXtH-tfxAUweeTAMu1pZOoknHoDVoXS1_KBvc_Ob8B35an0w</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2258746938</pqid></control><display><type>article</type><title>Fosfomycin for treatment of multidrug-resistant pathogens causing urinary tract infection: A real-world perspective and review of the literature</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Babiker, Ahmed ; Clarke, Lloyd ; Doi, Yohei ; Shields, Ryan K</creator><creatorcontrib>Babiker, Ahmed ; Clarke, Lloyd ; Doi, Yohei ; Shields, Ryan K</creatorcontrib><description>Among 47 patients with urinary tract infections (UTIs) due to multidrug-resistant (MDR) bacteria, treatment with fosfomycin resulted in clinical cure rates of 87% and 94% at 48 hours and 14 days, respectively. Response rates did not vary across pathogens. Our retrospective, observational findings support fosfomycin treatment against MDR pathogens causing UTIs.</description><identifier>ISSN: 0732-8893</identifier><identifier>EISSN: 1879-0070</identifier><identifier>DOI: 10.1016/j.diagmicrobio.2019.06.008</identifier><identifier>PMID: 31307867</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Anti-Bacterial Agents - therapeutic use ; CRE ; Drug Resistance, Multiple, Bacterial - drug effects ; ESBL ; Female ; Fosfomycin ; Fosfomycin - therapeutic use ; Humans ; Male ; Middle Aged ; Retrospective Studies ; Treatment Outcome ; Urinary Tract Infections - drug therapy ; Urinary Tract Infections - microbiology ; UTI ; VRE ; Young Adult</subject><ispartof>Diagnostic microbiology and infectious disease, 2019-11, Vol.95 (3), p.114856-114856, Article 114856</ispartof><rights>2019 Elsevier Inc.</rights><rights>Copyright © 2019 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c446t-90f0ca2a45e6928029dc9fbd6c933753bd3d3b67a93d03c6e0d25b5c02d8c2373</citedby><cites>FETCH-LOGICAL-c446t-90f0ca2a45e6928029dc9fbd6c933753bd3d3b67a93d03c6e0d25b5c02d8c2373</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.diagmicrobio.2019.06.008$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31307867$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Babiker, Ahmed</creatorcontrib><creatorcontrib>Clarke, Lloyd</creatorcontrib><creatorcontrib>Doi, Yohei</creatorcontrib><creatorcontrib>Shields, Ryan K</creatorcontrib><title>Fosfomycin for treatment of multidrug-resistant pathogens causing urinary tract infection: A real-world perspective and review of the literature</title><title>Diagnostic microbiology and infectious disease</title><addtitle>Diagn Microbiol Infect Dis</addtitle><description>Among 47 patients with urinary tract infections (UTIs) due to multidrug-resistant (MDR) bacteria, treatment with fosfomycin resulted in clinical cure rates of 87% and 94% at 48 hours and 14 days, respectively. Response rates did not vary across pathogens. Our retrospective, observational findings support fosfomycin treatment against MDR pathogens causing UTIs.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Anti-Bacterial Agents - therapeutic use</subject><subject>CRE</subject><subject>Drug Resistance, Multiple, Bacterial - drug effects</subject><subject>ESBL</subject><subject>Female</subject><subject>Fosfomycin</subject><subject>Fosfomycin - therapeutic use</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Retrospective Studies</subject><subject>Treatment Outcome</subject><subject>Urinary Tract Infections - drug therapy</subject><subject>Urinary Tract Infections - microbiology</subject><subject>UTI</subject><subject>VRE</subject><subject>Young Adult</subject><issn>0732-8893</issn><issn>1879-0070</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkUFv1DAQhS0EokvhLyCLE5eEiZ04cW9VoVCpEhc4W4492XqV2MF2WvVf9Cfj1RbEkZMlz3vzNO8j5EMDdQON-HSordP7xZkYRhdqBo2sQdQAwwuya4ZeVgA9vCQ76DmrhkHyM_ImpQNAw2QLr8kZbzj0g-h35Ok6pCksj8Z5OoVIc0SdF_SZhoku25ydjdu-iphcyrp8rzrfhT36RI3ekvN7ukXndXwsVm0ydX5Ck13wF_SSlmVz9RDibOmKMa3HyT1S7W0Z3Tt8OKbkO6Szyxh13iK-Ja8mPSd89_yek5_XX35cfatuv3-9ubq8rUzbilxJmMBoptsOhWQDMGmNnEYrjOS87_houeWj6LXkFrgRCJZ1Y2eA2cEw3vNz8vG0d43h14Ypq8Ulg_OsPYYtKca6oW-F5EORXpykpfCUIk5qjW4pJ6sG1JGIOqh_iagjEQVCFSLF_P45ZxsXtH-tfxAUweeTAMu1pZOoknHoDVoXS1_KBvc_Ob8B35an0w</recordid><startdate>201911</startdate><enddate>201911</enddate><creator>Babiker, Ahmed</creator><creator>Clarke, Lloyd</creator><creator>Doi, Yohei</creator><creator>Shields, Ryan K</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201911</creationdate><title>Fosfomycin for treatment of multidrug-resistant pathogens causing urinary tract infection: A real-world perspective and review of the literature</title><author>Babiker, Ahmed ; Clarke, Lloyd ; Doi, Yohei ; Shields, Ryan K</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c446t-90f0ca2a45e6928029dc9fbd6c933753bd3d3b67a93d03c6e0d25b5c02d8c2373</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Anti-Bacterial Agents - therapeutic use</topic><topic>CRE</topic><topic>Drug Resistance, Multiple, Bacterial - drug effects</topic><topic>ESBL</topic><topic>Female</topic><topic>Fosfomycin</topic><topic>Fosfomycin - therapeutic use</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Retrospective Studies</topic><topic>Treatment Outcome</topic><topic>Urinary Tract Infections - drug therapy</topic><topic>Urinary Tract Infections - microbiology</topic><topic>UTI</topic><topic>VRE</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Babiker, Ahmed</creatorcontrib><creatorcontrib>Clarke, Lloyd</creatorcontrib><creatorcontrib>Doi, Yohei</creatorcontrib><creatorcontrib>Shields, Ryan K</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Diagnostic microbiology and infectious disease</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Babiker, Ahmed</au><au>Clarke, Lloyd</au><au>Doi, Yohei</au><au>Shields, Ryan K</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Fosfomycin for treatment of multidrug-resistant pathogens causing urinary tract infection: A real-world perspective and review of the literature</atitle><jtitle>Diagnostic microbiology and infectious disease</jtitle><addtitle>Diagn Microbiol Infect Dis</addtitle><date>2019-11</date><risdate>2019</risdate><volume>95</volume><issue>3</issue><spage>114856</spage><epage>114856</epage><pages>114856-114856</pages><artnum>114856</artnum><issn>0732-8893</issn><eissn>1879-0070</eissn><abstract>Among 47 patients with urinary tract infections (UTIs) due to multidrug-resistant (MDR) bacteria, treatment with fosfomycin resulted in clinical cure rates of 87% and 94% at 48 hours and 14 days, respectively. Response rates did not vary across pathogens. Our retrospective, observational findings support fosfomycin treatment against MDR pathogens causing UTIs.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>31307867</pmid><doi>10.1016/j.diagmicrobio.2019.06.008</doi><tpages>1</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0732-8893 |
| ispartof | Diagnostic microbiology and infectious disease, 2019-11, Vol.95 (3), p.114856-114856, Article 114856 |
| issn | 0732-8893 1879-0070 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2258746938 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Adult Aged Aged, 80 and over Anti-Bacterial Agents - therapeutic use CRE Drug Resistance, Multiple, Bacterial - drug effects ESBL Female Fosfomycin Fosfomycin - therapeutic use Humans Male Middle Aged Retrospective Studies Treatment Outcome Urinary Tract Infections - drug therapy Urinary Tract Infections - microbiology UTI VRE Young Adult |
| title | Fosfomycin for treatment of multidrug-resistant pathogens causing urinary tract infection: A real-world perspective and review of the literature |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-22T21%3A07%3A25IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Fosfomycin%20for%20treatment%20of%20multidrug-resistant%20pathogens%20causing%20urinary%20tract%20infection:%20A%20real-world%20perspective%20and%20review%20of%20the%20literature&rft.jtitle=Diagnostic%20microbiology%20and%20infectious%20disease&rft.au=Babiker,%20Ahmed&rft.date=2019-11&rft.volume=95&rft.issue=3&rft.spage=114856&rft.epage=114856&rft.pages=114856-114856&rft.artnum=114856&rft.issn=0732-8893&rft.eissn=1879-0070&rft_id=info:doi/10.1016/j.diagmicrobio.2019.06.008&rft_dat=%3Cproquest_cross%3E2258746938%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2258746938&rft_id=info:pmid/31307867&rft_els_id=S0732889319302238&rfr_iscdi=true |